TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17699008
Drug: Control hepatitis
Normalized name: hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control hepatitis A vaccine (n = 1101)
Study: 9990561
Drug: Clozapine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (300 mg/day, increased to 600 and 900 mg/day if tolerated)
Study: 9990561
Drug: Conventional neuroleptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional neuroleptic (initial treatment for 6 weeks)
Study: 22955359
Drug: L. salivarius
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. salivarius LS01 (probiotic)
Study: 9316673
Drug: L-Dopa/benserazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Dopa/benserazide
Study: 2465445
Drug: 3-OH-HQ 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-OH-HQ 225 mg
Study: 2465445
Drug: 3-OH-HQ 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-OH-HQ 450 mg
Study: 2465445
Drug: 3-OH-HQ 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-OH-HQ 900 mg
Study: 29144152
Drug: Standard and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard and psychological treatment
Study: 26706860
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug and non-drug antidepressive treatment (control group)
Study: 8876264
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day prednisolone
Study: 1615179
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (5 mg) as one puff q.d.s. via inhaler
Study: 6380212
Drug: Phenobarbital 12
Normalized name: phenobarbital 120 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital 12 mg/kg
Study: 6380212
Drug: Phenobarbital 4
Normalized name: phenobarbital 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital 4 mg/kg
Study: 6380212
Drug: Phenobarbital 8
Normalized name: phenobarbital 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital 8 mg/kg
Study: 29161199
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray (64 μg/mL) twice daily for 6 weeks
Study: 18080054
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy (COT) with rabeprazole 20 mg
Study: 18080054
Drug: On-demand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand therapy (ODT) with rabeprazole 20 mg
Study: 12168126
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml line-clearing volume
Study: 12168126
Drug: 3.0 ml
Normalized name: HYDROGEN PEROXIDE 3.0 mL in 100 mL TOPICAL SPRAY [aramark Hydrogen Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 ml line-clearing volume
Study: 12168126
Drug: 4.0 ml
Normalized name: OCTINOXATE 7.5 mL in 100 mL / OCTISALATE 4.0 mL in 100 mL TOPICAL LIQUID [LONG LAST GLOSSWEAR SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 ml line-clearing volume
Study: 7876649
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (HM175) administered at 0, 1, and 6 months
Study: 7876649
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (HM175) administered at 0, 1, and 12 months
Study: 7876649
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (HM175)
Study: 23464715
Drug: Oral synbiotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral synbiotic (Agri-King Synbiotic, AKSB)
Study: 20890244
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg monthly) plus PDT
Study: 19660610
Drug: Simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin plus Fenofibrate (20 mg simvastatin + 160 mg fenofibrate)
Study: 19660610
Drug: Simvastatin monotherapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin monotherapy (20 mg)
Study: 8489751
Drug: Levonova (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonova (20 micrograms levonorgestrel daily)
Study: 28604115
Drug: xyloglucan-based nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: xyloglucan-based nasal spray
Study: 28604115
Drug: saline nasal
Normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline nasal spray
Study: 25888571
Drug: White blood
Normalized name: Human white blood cell product
Approvals — FDA: no, EMA: no, PMDA: no
Description: White blood cell count >10.6 × 10^9/L
Study: 25888571
Drug: PAI-1 >12.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAI-1 >12.2 IU/mL
Study: 22776634
Drug: Lurasidone 120
Normalized name: lurasidone 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 120 mg/d
Study: 22776634
Drug: Quetiapine extended-release
Normalized name: Quetiapine Extended-Release Tablets
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine extended-release 600 mg/d
Study: 22776634
Drug: Lurasidone 40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 40-120 mg/d
Study: 19820238
Drug: Fixed-dose regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose regimens in RCTs
Study: 11934658
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol combined with gestodene
Study: 11934658
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol combined with gestodene
Study: 11934658
Drug: Piperazine, estrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperazine, estrone sulfate in combination with norethisterone
Study: 2189248
Drug: Proguanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil at 200 mg/d combined with sulphafurazole at 25 mg/kg/d
Study: 2189248
Drug: Proguanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil at 200 mg/d combined with sulphamethoxazole at 25 mg/kg/d
Study: 2189248
Drug: Proguanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil at 200 mg/d combined with sulphamethoxazole at 10 mg/kg/d
Study: 17264336
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy (CT) and radiotherapy (RT)
Study: 17264336
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy (CT) followed by radiotherapy (RT)
Study: 9329641
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg vitamin C/day
Study: 9329641
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g vitamin C/day
Study: 9329641
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (both doses)
Study: 8172789
Drug: Epirubicin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (100 mg/m2 every three weeks, escalating to a maximum of 140 mg/m2)
Study: 8172789
Drug: Fluorouracil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil (500 mg/m2 days 1‐5 every three weeks, escalating to a maximum of 700 mg/m2)
Study: 29880257
Drug: KaempMax™ (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: KaempMax™ (100 mg daily for 30 days)
Study: 25239491
Drug: Bilateral intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral intramuscular administration of cytokine‐mobilized CD133+ cells (50-400 million cells)
Study: 25239491
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injections, sham leukapheresis, and intramuscular injection of placebo buffered solution
Study: 18819393
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO) for 3 days (twice a day) using a monoplace chamber under pressures of 1.7‐1.9 ATA
Study: 18819393
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment protocol (Control)
Study: 12012623
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 4 mg/day (group A)
Study: 12012623
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 6 mg/day (group B)
Study: 10631416
Drug: Paracetamol 2
Normalized name: Paracetamol 24 mg/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 2 g through a nasogastric tube
Study: 10631416
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol 2 g
Study: 10631416
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of paracetamol (6 g/day) on day 1 after cardiac surgery
Study: 30575239
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with irinotecan (60 mg/m2 on days 1 and 8) and nedaplatin (80 mg/m2 on day 1 of every 21‐day cycle) followed by radical hysterectomy and adjuvant chemotherapy.
Study: 22079390
Drug: Nutraceuticals (coenzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceuticals (coenzyme Q(10), RRR‐α‐tocopherol, selenium aspartate, and L‐methionine) with cryotherapy for HPV warts
Study: 22079390
Drug: Nutraceuticals (coenzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceuticals (coenzyme Q(10), RRR‐α‐tocopherol, selenium aspartate, and L‐methionine) with acyclovir for herpes infections
Study: 22079390
Drug: Nutraceuticals (coenzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceuticals (coenzyme Q(10), RRR‐α‐tocopherol, selenium aspartate, and L‐methionine)
Study: 19671308
Drug: Glucagon injection
Normalized name: glucagon Injection
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon injection
Study: 17498005
Drug: KRN321 (darbepoetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRN321 (darbepoetin alfa) administered at extended dose intervals (once per week or once every two weeks)
Study: 15170885
Drug: 1 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/m2 MTX as a 24-hr infusion
Study: 15170885
Drug: 2 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/m2 MTX as a 24-hr infusion
Study: 11587466
Drug: Classical SDD
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical SDD regimen (tobramycin 80 mg, polymyxin E 100 mg, amphotericin B 500 mg)
Study: 11587466
Drug: Modified SDD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified SDD regimen with mupirocin (2% mupirocin ointment applied four times daily in nostrils and modified oral paste)
Study: 9838776
Drug: Spray group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray group
Study: 782468
Drug: sodium pentosan
Normalized name: Pentosan Polysulfate Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium pentosan polysulphate/nicotinic acid combination (Compuron)
Study: 11086616
Drug: SF-36 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SF-36 plus a form assessing amount of treatment received
Study: 23086244
Drug: Conventional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional management plus intravenous infusion of octreotide, 50 μg/h for 72 hours (obese-C+O)
Study: 15752371
Drug: Amyl nitrite
Normalized name: Amyl Nitrite
DrugBank: Amyl Nitrite (DB01612)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amyl nitrite (0.2 ml inhaled for 30 s)
Study: 15752371
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (0.5 mg for 3 min)
Study: 10730758
Drug: VML 295
Approvals — FDA: no, EMA: no, PMDA: no
Description: VML 295 (LY-293111) 200 mg twice daily for 8 weeks
Study: 9377614
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 0.1%-salicylic acid 5% ointment, applied twice daily for 21 days
Study: 9377614
Drug: Fluocinonide 0.05%
Normalized name: FLUOCINONIDE 0.05% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocinonide 0.05% ointment, applied twice daily for 21 days
Study: 3873372
Drug: Aspirin (3.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3.9 g/day)
Study: 3873372
Drug: Aspirin (1.95
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1.95 g/day) with Acetaminophen (1.95 g/day)
Study: 3873372
Drug: Aspirin (2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (2.6 g/day) with Acetaminophen (2.6 g/day)
Study: 27255504
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention including academic detailing, medicine review with web-based pharmaceutical treatment algorithms, and tailored patient information leaflets.
Study: 20515625
Drug: Interventional training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional training program for primary care physicians on beta-blocker use
Study: 12540404
Drug: Dual-fortified salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-fortified salt (DFS) containing 25 micro g iodine/g salt and 1 mg iron/g salt
Study: 8707361
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (AMB) 1 mg/kg bw/day for 20 days
Study: 8707361
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (AMB) 0.75 mg/kg bw/day for 20 days
Study: 8707361
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (AMB) 0.5 mg/kg bw/day for 20 days
Study: 26967690
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg daily) for 6 weeks
Study: 16516511
Drug: Loratadine (10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10mg daily)
Study: 16516511
Drug: Montelukast (10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10mg daily)
Study: 1977089
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg b.d.
Study: 341950
Drug: mianserin 60
Normalized name: mianserin 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin 60 mg daily
Study: 341950
Drug: imipramine 150
Normalized name: imipramine pamoate 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipramine 150 mg daily
Study: 31527377
Drug: Bifiprost® +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifiprost® + Serenoa Repens 320 mg
Study: 31527377
Drug: Serenoa Repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa Repens 320 mg alone
Study: 27788498
Drug: Irinotecan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan plus cisplatin (IP) followed by octreotide long-acting release (LAR) maintenance treatment
Study: 27788498
Drug: Irinotecan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan plus cisplatin (IP) followed by octreotide LAR maintenance treatment in high proliferation NET group
Study: 27788498
Drug: Irinotecan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan plus cisplatin (IP) followed by octreotide LAR maintenance treatment in poorly differentiated NEC (PDNEC) group
Study: 16737936
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of oral valganciclovir
Study: 16737936
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of intravenous ganciclovir
Study: 3527086
Drug: Azathioprine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (1 mg/kg for the first month, 2 mg/kg for the second month)
Study: 25424809
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine with prophylactic paracetamol
Study: 25424809
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine without prophylactic paracetamol
Study: 25424809
Drug: Routine infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine infant vaccines (DTaP-HBV-IPV/Hib and PCV7) with 4CMenB
Study: 25424809
Drug: Routine infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine infant vaccines (DTaP-HBV-IPV/Hib and PCV7) with MenC
Study: 12114877
Drug: Deep injection
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep injection of radiotracer (group B)
Study: 12114877
Drug: Superficial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial injection of radiotracer (group A)
Study: 12114877
Drug: Deep injection
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep injection of radiotracer (in outer quadrant patients)
Study: 7757308
Drug: Nimodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (30 mg t.i.d.) with Propranolol (40 mg t.i.d.)
Study: 30070034
Drug: Micro-needle mesotherapy
Normalized name: Salicylic Acid 0.002 TOPICAL PATCH [Egg micro needle soothing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-needle mesotherapy with 20% L-ascorbic acid serum
Study: 30070034
Drug: No-needle mesotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-needle mesotherapy with 20% L-ascorbic acid serum
Study: 29161260
Drug: Delivery arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivery arm (direct distribution of an oral HIVST from the peer educator)
Study: 29161260
Drug: Coupon arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coupon arm (a coupon for collection of an oral HIVST from a health clinic/pharmacy)
Study: 25627884
Drug: Yakult® (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yakult® (Treatment A)
Study: 25627884
Drug: Batavito® (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batavito® (Treatment B)
Study: 25627884
Drug: Yakult® (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yakult® (Treatment C)
Study: 25627884
Drug: Batavito® (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batavito® (Treatment D)
Study: 22746245
Drug: Microdose lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdose lithium treatment (300 μg, administered once daily for 15 months)
Study: 22746245
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified, but implied to be without lithium treatment)
Study: 21684478
Drug: Atorvastatin 40mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 40mg for 8 months
Study: 16468063
Drug: Shoulder-to-hand distance
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shoulder-to-hand distance (l)
Study: 12846597
Drug: Diazepam 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.1 mg/kg (IV infusion)
Study: 8364132
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day ZnSO4
Study: 8364132
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day ZnSO4
Study: 3538460
Drug: misonidazole (1
Normalized name: Fluoromisonidazole (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: misonidazole (1 g/m2 body surface)
Study: 29728296
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Buzzy® and animated cartoon
Study: 25370571
Drug: Psychological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological intervention (cognitive behavioural therapy combined with counselling techniques)
Study: 8911981
Drug: Glimepiride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (5 mg)
Study: 31178508
Drug: Kikyo-to (KKT)
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kikyo-to (KKT) 2.5 g
Study: 19688837
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.3 mg/kg body weight, maximum 10 mg)
Study: 9695587
Drug: Adjuvant laferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant laferon therapy (intraperitoneal and systemic administration)
Study: 8077355
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg L-692,429, i.v. preceded by 4 days of prednisolone (20 mg, orally, three times daily)
Study: 8077355
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg L-692,429 preceded by prednisolone only
Study: 8077355
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg L-692,429 in the absence of steroid
Study: 2491941
Drug: (-)-deprenyl (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-deprenyl (30 mg/d)
Study: 31068063
Drug: VTC-administered ADAS-cog
Normalized name: Adasuve
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VTC-administered ADAS-cog
Study: 31068063
Drug: FTF-administered ADAS-cog
Normalized name: Adasuve
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FTF-administered ADAS-cog
Study: 24258468
Drug: Strefen lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strefen lozenges
Study: 24258468
Drug: Siccoral spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siccoral spray
Study: 22023081
Drug: Haberlea extract
Normalized name: Haberlea rhodopensis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haberlea extract (3% in cream)
Study: 18174071
Drug: Midpalatal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midpalatal implants
Study: 8963856
Drug: Sequential surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential surgery (SS)
Study: 2045624
Drug: Pyridostigmine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (60 mg po)
Study: 2045624
Drug: PD +
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD + GHRH (60 mg PD orally 60 min before GHRH)